5334-30-5 Usage
Description
1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine is a chemical compound belonging to the class of pyrazolopyrimidines. It is characterized by its unique molecular structure, which features a phenyl group attached to a pyrazolo[3,4-d]pyrimidine core with an amine functional group at the 4-position. 1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine has potential applications in various fields due to its structural properties and reactivity.
Uses
Used in Pharmaceutical Industry:
1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine is used as an intermediate in the preparation of various enzymatic inhibitors. It plays a crucial role in the development of therapeutic agents targeting specific enzymes, which are often involved in disease progression.
Used in Biochemical Research:
In the field of biochemical research, 1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine serves as a valuable compound for studying the structure-activity relationships of enzymatic inhibitors. Its unique structure allows researchers to investigate the interactions between the compound and its target enzymes, leading to a better understanding of the underlying mechanisms and the potential for designing more effective inhibitors.
Used in the Development of Anticancer Agents:
1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine is used as a building block for the synthesis of small molecule inhibitors targeting the Src family of non-receptor tyrosine kinases. These kinases are known to regulate cell adhesion, growth, and differentiation through the activation of multiple intracellular signaling pathways. Abnormal activation of Src kinases has been associated with various cancers, making them an attractive therapeutic target. By incorporating 1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine into the structure of Src kinase inhibitors, researchers aim to develop more potent and selective agents to combat cancer.
Used in Drug Delivery Systems:
1-Phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine may also find application in the development of drug delivery systems, particularly for the targeted delivery of enzymatic inhibitors. Its structural properties could be exploited to enhance the solubility, stability, and bioavailability of these inhibitors, ultimately improving their therapeutic efficacy.
Biological Activity
Negative control for the src kinase inhibitor PP 2 (3-(4-chlorophenyl)1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine ). Inhibits EGFR kinase (IC 50 = 2.7 μ M).
Check Digit Verification of cas no
The CAS Registry Mumber 5334-30-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,3,3 and 4 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 5334-30:
(6*5)+(5*3)+(4*3)+(3*4)+(2*3)+(1*0)=75
75 % 10 = 5
So 5334-30-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H9N5/c12-10-9-6-15-16(11(9)14-7-13-10)8-4-2-1-3-5-8/h1-7H,(H2,12,13,14)
5334-30-5Relevant articles and documents
Synthesis and characterization of two novel organic-inorganic compounds based on tetrahexyl and Tetraheptyl ammonium ions and the preyssler anion and their catalytic activities in the synthesis of 4-aminopyrazolo[3,4-d]- pyrimidines
Bamoharram, Fatemeh Farrash
, p. 2509 - 2519 (2010)
Two novel organic-inorganic compounds based on tetrahexylammonium (THA) and tetraheptylammonium (THPA) ions and the Preyssler anion, [NaP5W30O110]14-, were synthesized and formulated as (THA)7.7H6.3 [NaP5W30O110] (A) and (THPA)7.5 H6.5[N aP5W30O110] (B).
Pyrimidine compound with pyrazolo [3, 4-d] as parent nucleus and preparation method thereof
-
Paragraph 0034-0036, (2020/02/10)
The invention discloses a pyrimidine compound with pyrazolo [3, 4-d] as a parent nucleus and a preparation method thereof. The invention relates to pyrazolo [3, 4-d] pyrimidine derivatives shown in ageneral formula (I), a preparation method of the pyrazol
Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; Design, synthesis and biological evaluation as potential anti-inflammatory agents
Abdelazeem, Ahmed H.,Abdelatef, Shaimaa A.,El-Saadi, Mohammed T.,Omar, Hany A.,Khan, Shabana I.,McCurdy, Christopher R.,El-Moghazy, Samir M.
, p. 197 - 211 (2014/07/08)
A novel set of 4-substituted-1-phenyl-pyrazolo[3,4-d]pyrimidine and 5-substituted-1-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives were synthesized and evaluated as potential anti-inflammatory agents. The newly prepared compounds were assessed through the examination of their in vitro inhibition of four targets; cyclooxygenases subtypes (COX-1 and COX-2), inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB). Compounds 8a, 10c and 13c were the most potent and selective ligands against COX-2 with inhibition percentages of 79.6%, 78.7% and 78.9% at a concentration of 2 μM respectively, while compound 13c significantly inhibited both COX subtypes. On the other hand, fourteen compounds showed high iNOS inhibitory activities with IC50 values in the range of 0.22-8.5 μM where the urea derivative 11 was the most active compound with IC50 value of 0.22 μM. Most of the tested compounds were found to be devoid of inhibitory activity against NF-kB. Moreover, almost all compounds were not cytotoxic, (up to 25 μg/ml), against a panel of normal and cancer cell lines. The in silico docking results were in agreement with the in vitro inhibitory activities against COXs and iNOS enzymes. The results of in vivo anti-inflammatory and antinociceptive studies were consistent with that of in vitro studies which confirmed that compounds 8a, 10c and 13c have significant anti-inflammatory and analgesic activities comparable to that of the control, ketorolac. Taken together, dual inhibition of COXs and iNOS with novel pyrazolopyrimidine derivatives is a valid strategy for the development of anti-inflammatory/ analgesic agents with the probability of fewer side effects.
